Management of Co‑administration of Tirzepatide (Mounjaro) and Teprotumumab (Tepezza)Hyperglycemia Risk and MonitoringGastrointestinal Adverse‑Effect OverlapMuscle‑Spasm OverlapBaseline Assessment Prior to Combined TherapyOngoing Monitoring During Concurrent TherapyDose‑Adjustment RecommendationsClinical Pitfalls to Avoid